-
Je něco špatně v tomto záznamu ?
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
R. Li, PJ. Hensley, S. Gupta, H. Al-Ahmadie, M. Babjuk, PC. Black, M. Brausi, KK. Bree, MI. Fernández, CC. Guo, A. Horowitz, DL. Lamm, SP. Lerner, Y. Lotan, P. Mariappan, D. McConkey, LS. Mertens, C. Mir, JS. Ross, M. O'Donnell, J. Palou, K....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, přehledy
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- BCG vakcína * terapeutické užití MeSH
- cystektomie MeSH
- invazivní růst nádoru * MeSH
- léčba šetřící orgány * MeSH
- lidé MeSH
- nádory močového měchýře neinvadující svalovinu MeSH
- nádory močového měchýře * farmakoterapie patologie MeSH
- výběr pacientů * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
BACKGROUND AND OBJECTIVE: There has been a recent surge in the development of agents for bacillus Calmette-Guérin-unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC). Critical assessment of these agents and practical recommendations for optimal selection of patients and therapies are urgently needed, especially in the absence of randomized trials on bladder-sparing treatment (BST) options. METHODS: A global committee of bladder cancer experts was assembled to develop recommendations on BST for BCG-U NMIBC. Working groups reviewed the literature and developed draft recommendations, which were then voted on by International Bladder Cancer Group (IBCG) members using a modified Delphi process. During a live meeting in August 2023, voting results and supporting evidence were presented, and recommendations were refined on the basis of meeting discussions. Final recommendations achieved >75% agreement during the meeting, and some were further refined via web conferences and e-mail discussions. KEY FINDINGS AND LIMITATIONS: There is currently no single optimal agent for patients with BCG-U disease who seek to avoid radical cystectomy (RC). BST selection should be personalized, taking into account individual patient characteristics and preferences, tumor attributes, and efficacy/toxicity data for the agents available. For patients with BCG-U carcinoma in situ (CIS), gemcitabine/docetaxel (GEM/DOCE), nadofaragene firadenovec (NFF), and nogapendekin alfa inbakicept-pmln (NAI) + BCG are recommended; because of its systemic toxicity, pembrolizumab should only be offered after other options are exhausted. For patients with BCG-U papillary-only tumors, GEM/DOCE, NFF, NAI + BCG, single-agent chemotherapy, hyperthermic mitomycin C, and pembrolizumab are recommended. Given the modest efficacy of available options, clinical trial participation is encouraged. For unapproved agents with reported data, IBCG recommendations await the final results of pivotal trials. CONCLUSIONS AND CLINICAL IMPLICATIONS: The IBCG consensus recommendations provide practical guidance on BST for BCG-U NMIBC.
BCG Oncology PC University of Arizona College of Medicine Phoenix AZ USA
Carver College of Medicine University of Iowa Iowa City IA USA
Department of Genitourinary Oncology H Lee Moffitt Cancer Center Tampa FL USA
Department of Genitourinary Pathology University of Texas MD Anderson Cancer Center Houston TX USA
Department of Urologic Sciences University of British Columbia Vancouver Canada
Department of Urology Clinica Alemana Universidad del Desarrollo Santiago Chile
Department of Urology Fundació Puigvert Universitat Autònoma de Barcelona Barcelona Spain
Department of Urology Hesperia Hospital Modena Italy
Department of Urology Hospital Universitario La Ribera Valencia Spain
Department of Urology Ohio State University Columbus OH USA
Department of Urology Rush University Medical Center Chicago IL USA
Department of Urology University of Kentucky College of Medicine Lexington KY USA
Department of Urology University of Texas Health San Antonio San Antonio TX USA
Department of Urology University of Texas MD Anderson Cancer Center Houston TX USA
Department of Urology UT Southwestern Medical Center Dallas TV USA
Faculty of Medicine Kagawa University Kagawa Japan
Foundation Medicine Boston MA USA
Johns Hopkins Greenberg Bladder Cancer Institute Baltimore MD USA
Memorial Hospital Hollywood FL USA
Moffitt Cancer Center Morsani College of Medicine University of South Florida Tampa FL USA
Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam The Netherlands
North York General Hospital Toronto Canada
Scott Department of Urology Dan L Duncan Cancer Center Baylor College of Medicine Houston TX USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003293
- 003
- CZ-PrNML
- 005
- 20250206104231.0
- 007
- ta
- 008
- 250121s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2024.08.001 $2 doi
- 035 __
- $a (PubMed)39183090
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Li, Roger $u Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
- 245 10
- $a Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection / $c R. Li, PJ. Hensley, S. Gupta, H. Al-Ahmadie, M. Babjuk, PC. Black, M. Brausi, KK. Bree, MI. Fernández, CC. Guo, A. Horowitz, DL. Lamm, SP. Lerner, Y. Lotan, P. Mariappan, D. McConkey, LS. Mertens, C. Mir, JS. Ross, M. O'Donnell, J. Palou, K. Pohar, G. Steinberg, M. Soloway, PE. Spiess, RS. Svatek, WS. Tan, R. Taoka, R. Buckley, AM. Kamat
- 520 9_
- $a BACKGROUND AND OBJECTIVE: There has been a recent surge in the development of agents for bacillus Calmette-Guérin-unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC). Critical assessment of these agents and practical recommendations for optimal selection of patients and therapies are urgently needed, especially in the absence of randomized trials on bladder-sparing treatment (BST) options. METHODS: A global committee of bladder cancer experts was assembled to develop recommendations on BST for BCG-U NMIBC. Working groups reviewed the literature and developed draft recommendations, which were then voted on by International Bladder Cancer Group (IBCG) members using a modified Delphi process. During a live meeting in August 2023, voting results and supporting evidence were presented, and recommendations were refined on the basis of meeting discussions. Final recommendations achieved >75% agreement during the meeting, and some were further refined via web conferences and e-mail discussions. KEY FINDINGS AND LIMITATIONS: There is currently no single optimal agent for patients with BCG-U disease who seek to avoid radical cystectomy (RC). BST selection should be personalized, taking into account individual patient characteristics and preferences, tumor attributes, and efficacy/toxicity data for the agents available. For patients with BCG-U carcinoma in situ (CIS), gemcitabine/docetaxel (GEM/DOCE), nadofaragene firadenovec (NFF), and nogapendekin alfa inbakicept-pmln (NAI) + BCG are recommended; because of its systemic toxicity, pembrolizumab should only be offered after other options are exhausted. For patients with BCG-U papillary-only tumors, GEM/DOCE, NFF, NAI + BCG, single-agent chemotherapy, hyperthermic mitomycin C, and pembrolizumab are recommended. Given the modest efficacy of available options, clinical trial participation is encouraged. For unapproved agents with reported data, IBCG recommendations await the final results of pivotal trials. CONCLUSIONS AND CLINICAL IMPLICATIONS: The IBCG consensus recommendations provide practical guidance on BST for BCG-U NMIBC.
- 650 12
- $a nádory močového měchýře $x farmakoterapie $x patologie $7 D001749
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a BCG vakcína $x terapeutické užití $7 D001500
- 650 12
- $a výběr pacientů $7 D018579
- 650 12
- $a invazivní růst nádoru $7 D009361
- 650 12
- $a léčba šetřící orgány $7 D059351
- 650 _2
- $a adjuvancia imunologická $x terapeutické užití $7 D000276
- 650 _2
- $a cystektomie $7 D015653
- 650 _2
- $a nádory močového měchýře neinvadující svalovinu $7 D000093284
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hensley, Patrick J $u Department of Urology, University of Kentucky College of Medicine, Lexington, KY, USA
- 700 1_
- $a Gupta, Shilpa $u Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
- 700 1_
- $a Al-Ahmadie, Hikmat $u Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Babjuk, Marko $u Department of Urology, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czechia
- 700 1_
- $a Black, Peter C $u Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
- 700 1_
- $a Brausi, Maurizio $u Department of Urology, Hesperia Hospital, Modena, Italy
- 700 1_
- $a Bree, Kelly K $u Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 700 1_
- $a Fernández, Mario I $u Department of Urology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile
- 700 1_
- $a Guo, Charles C $u Department of Genitourinary Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 700 1_
- $a Horowitz, Amir $u Departments of Immunology & Immunotherapy and Oncological Sciences, Lipschultz Precision Immunology Institute and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 700 1_
- $a Lamm, Donald L $u BCG Oncology PC, University of Arizona College of Medicine, Phoenix, AZ. USA
- 700 1_
- $a Lerner, Seth P $u Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
- 700 1_
- $a Lotan, Yair $u Department of Urology, UT Southwestern Medical Center, Dallas, TV, USA
- 700 1_
- $a Mariappan, Paramananthan $u Edinburgh Bladder Cancer Surgery, University of Edinburgh, Department of Urology, Western General Hospital, Edinburgh, UK
- 700 1_
- $a McConkey, David $u Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA
- 700 1_
- $a Mertens, Laura S $u Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Mir, Carmen $u Department of Urology, Hospital Universitario La Ribera, Valencia, Spain
- 700 1_
- $a Ross, Jeffrey S $u Upstate Medical University, Syracuse, NY, USA; Foundation Medicine, Boston, MA USA
- 700 1_
- $a O'Donnell, Michael $u Carver College of Medicine, University of Iowa, Iowa City, IA, USA
- 700 1_
- $a Palou, Joan $u Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Pohar, Kamal $u Department of Urology, Ohio State University, Columbus, OH, USA
- 700 1_
- $a Steinberg, Gary $u Department of Urology, Rush University Medical Center, Chicago, IL, USA
- 700 1_
- $a Soloway, Mark $u Memorial Hospital, Hollywood, FL, USA
- 700 1_
- $a Spiess, Philippe E $u Moffitt Cancer Center, Morsani College of Medicine, University of South Florida Tampa, FL, USA
- 700 1_
- $a Svatek, Robert S $u Department of Urology, University of Texas Health San Antonio, San Antonio, TX, USA
- 700 1_
- $a Tan, Wei Shen $u Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 700 1_
- $a Taoka, Rikiya $u Faculty of Medicine, Kagawa University, Kagawa, Japan
- 700 1_
- $a Buckley, Roger $u North York General Hospital, Toronto, Canada
- 700 1_
- $a Kamat, Ashish M $u Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 86, č. 6 (2024), s. 516-527
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39183090 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104226 $b ABA008
- 999 __
- $a ok $b bmc $g 2263196 $s 1239300
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 86 $c 6 $d 516-527 $e 20240824 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20250121
